Skip to main content

Table 2 Median survival as a function of patient characteristics

From: The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer

Categorical variables Median survival in months 95 % CI P-value
Serum vitamin D    0.06
 > = 20 ng/ml 12.8 10.8–14.7  
 <20 ng/ml 11.7 8.6–14.7  
Gender    0.04*
 Male 11.7 10.2–13.2  
 Female 13.5 11.2–15.8  
Stage    <0.001*
 III 20.1 12.9–27.3  
 IV 10.8 9.2–12.4  
CTCA hospital    <0.001*
 Philadelphia, PA 38.2 4.1–72.3  
 Zion, IL 12.4 10.6–14.1  
 Tulsa, OK 7.4 4.2–10.5  
Histologic subtype    0.002*
 Adenocarcinoma 12.8 11.2–14.4  
 Squamous cell 11.8 7.7–15.9  
 Others 7.2 3.7–10.7  
SGA    <0.001*
 Well–nourished 15.2 12.1–18.3  
 Moderately-severely malnourished 8.0 6.2–9.9  
ECOG score    <0.001*
 0–1 14.3 12.1–16.5  
 2–4 8.0 6.2–9.8  
Season of diagnosis    0.73
 Summer 11.6 8.4–14.8  
 Fall 11.7 8.3–15.1  
 Winter 12.6 8.9–16.3  
 Spring 12.7 10.2–15.3  
Smoking status    0.02*
 Never 19.4 10.8–27.9  
 Former 11.0 9.4–12.6  
 Current 11.7 9.3–14.1  
Vitamin D supplementation at diagnosis    0.27
 Yes 13.6 12.4–14.9  
 No 10.6 8.9–12.5  
  1. (SGA Subjective Global Assessment, ECOG Eastern Cooperative Oncology Group, CTCA Cancer Treatment Centers of America, PA Pennsylvania, IL Illinois, OK Oklahoma, ng/ml nanograms per milliliter, CI Confidence Interval)
  2. *P < = 0.05